α-Synuclein Seeding Activity in Fixed Antemortem Skin Biopsies From Patients With Synucleinopathies

Neurodegenerative diseases like Parkinson's, dementia with Lewy bodies, and multiple system atrophy share a common, destructive feature: a protein called alpha-synuclein. In a healthy brain, this protein performs normal functions, but in these illnesses, it misfolds and clumps together into toxic aggregates. These clumps act like a contagious seed, spreading from one cell to another and eventually causing the brain cells to fail. For decades, doctors have relied on clinical symptoms to diagnose these conditions, but a definitive confirmation has usually required examining brain tissue after a person has died. However, scientists have recently discovered that these harmful protein clumps are not confined to the brain; they also accumulate in the peripheral nervous system, including the tiny nerve fibers found in the skin. This realization opened a door to less invasive testing, allowing researchers to look for these disease markers in living patients through small skin samples.

The challenge, however, has been that the amount of this toxic protein in the skin is incredibly small, often too faint to be seen with standard staining methods. To solve this, researchers developed a technique called a seed amplification assay. Imagine a single drop of ink in a bucket of water; it is nearly invisible. But if that drop contains a substance that can turn the entire bucket of water into ink, you can detect it easily. This is what the assay does: it takes a tiny sample of skin and provides the right conditions for any existing toxic protein seeds to multiply rapidly, creating a signal strong enough to measure. While this method has worked well on fresh or frozen skin samples, a vast archive of medical history exists in the form of skin biopsies that have been preserved in a chemical fixative. These fixed samples are the standard for pathology labs, but it was unclear whether the chemical process used to preserve them would destroy the very seeds researchers hoped to find.

A team of researchers set out to answer this question by testing whether they could still detect the activity of these protein seeds in skin samples that had been fixed with paraformaldehyde, the standard preservative used in hospitals. They gathered skin biopsy sections from living patients who had been diagnosed with Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy, as well as from healthy individuals. The team applied an optimized version of the amplification test to these fixed tissues. They first confirmed that the toxic, phosphorylated form of the protein was indeed present in the nerve fibers of the skin, appearing as red signals alongside the green outlines of the nerves. Then, they introduced the fixed tissue samples into the reaction mixture to see if they could trigger the amplification process.

The results showed that the fixed tissue retained the ability to act as a seed, though the process was slightly slower and less intense than in fresh tissue. In this specific group of patients, the test successfully identified the presence of the toxic seeds in 70 percent of the Parkinson's cases, 80 percent of the dementia with Lewy bodies cases, and 80 percent of the multiple system atrophy cases. Among the healthy control group, the test correctly identified 80 percent of the individuals as negative, meaning it did not falsely flag them as having the disease. The researchers also looked at whether the strength of the signal from the test matched how sick the patients were. They found that a stronger signal was associated with more advanced stages of motor impairment, as measured by a standard rating scale, but the signal did not show a clear link to cognitive scores or the sheer amount of protein visible under a microscope.

This study demonstrates that the chemical preservation of skin tissue does not erase the biological activity of the toxic protein seeds. This is a significant finding because it means that the vast repositories of fixed skin biopsies already stored in medical archives can now be re-examined using this powerful new tool. It allows scientists to gain two different types of information from the same piece of tissue: a visual map of where the protein is located and a functional measurement of how active those proteins are. While the study was conducted on a selected group of patients and cannot yet be used as a standalone diagnostic test for the general population, it proves that the method works on fixed samples. The ability to detect these seeds in preserved tissue offers a new way to study the history of these diseases and may help researchers better understand how the pathology spreads and evolves over time.